LitAlert ~~ GeneLit.com

Patient cost-sharing during poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA.
Am J Obstet Gynecol. 2021 Feb 4. pii: S0002-9378(21)00086-7. doi: 10.1016/j.ajog.2021.01.029. Epub ahead of print.

Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – A systematic review and meta-analysis.
Davey MG, Davey CM, Ryan EJ, Lowery AJ, Kerin MJ.
Breast. 2021 Feb 4:S0960-9776(21)00015-1. doi: 10.1016/j.breast.2021.02.001. Epub ahead of print.

A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Józwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC.
Int J Cancer. 2021 Feb 4. doi: 10.1002/ijc.33498. Epub ahead of print.

Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E.
Cancers (Basel). 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583.

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Chen Z, Wang X, Li X, Zhou Y, Chen K.
J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.